☆ 4.7 Editorial Material

Treatment De-escalation in AQP4-Ab Neuromyelitis Optica Spectrum Disorder

NEUROLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder

Stanislas Demuth et al.

Summary: This study examined the risk of disease reactivation in patients with NMOSD undergoing de-escalation of rituximab. The findings suggest that most de-escalation regimens are associated with an increased risk of disease reactivation.

NEUROLOGY (2023)

添加到收藏夹

Review Clinical Neurology

New therapies for neuromyelitis optica spectrum disorder

Michael Levy et al.

Summary: Neuromyelitis optica spectrum disorder is a rare autoimmune disease affecting the CNS, with recent trials showing benefits of new therapies in preventing future attacks. However, differences in efficacy, safety, tolerability, and practical considerations of these therapies may impact their use in real-world populations of patients. Future research should focus on unmet needs, including aquaporin-4 seronegative disease and treatments for acute relapses and recovery from autoimmune attacks in the CNS.

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Masayuki Tahara et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study

Renata Barbosa Paolilo et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

添加到收藏夹

Article Clinical Neurology

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders

Jacqueline Palace et al.

BRAIN (2019)

添加到收藏夹

Article Clinical Neurology

Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica

Richard K. Burt et al.

NEUROLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Takashi Yamamura et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Clinical Neurology

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Dean M. Wingerchuk et al.

NEUROLOGY (2015)

添加到收藏夹

Article Clinical Neurology

Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica Multicenter Study of Treatment Efficacy

Maureen A. Mealy et al.

JAMA NEUROLOGY (2014)

添加到收藏夹

Article Clinical Neurology

A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder

Su-Hyun Kim et al.

JAMA NEUROLOGY (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.